Brief: Voyager Therapeutics Reports Third Quarter Financial And Operating Results
08/11/2022 12:37
Nov 8 (Reuters) - Voyager Therapeutics Inc VYGR.O :
* VOYAGER THERAPEUTICS REPORTS THIRD QUARTER 2022 FINANCIAL
AND
OPERATING RESULTS
* VOYAGER THERAPEUTICS - SEES CASH, CASH EQUIVALENTS,
REIMBURSEMENT FOR DEVELOPMENT COSTS UNDER NEUROCRINE DEAL
SUFFICIENT TO MEET EXPENSES INTO 2024
* BEYOND NEUROCRINE, RUNWAY COULD IMPROVE FURTHER BASED ON
POTENTIAL FUTURE MILESTONES IN 2023 FROM EXISTING COLLABORATIONS
* QTRLY NET INCOME PER SHARE, DILUTED $ 0.45
* Q3 EARNINGS PER SHARE VIEW $-0.32 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX9CwdXR
Further company coverage: VYGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview